HRSA Accepting Comments on Stem Cell Therapeutic Outcomes Database Through May 17

The Health Resources and Services Administration is accepting comments related to the burden estimate for the Stem Cell Therapeutic Outcomes Database (SCTOD) through May 17. Through the SCTOD, the Center for International Blood and Marrow Transplant Research collects data from transplant centers for ongoing analysis of transplant outcomes to improve the treatment, survival and quality of life for patients who may benefit from cellular therapies.

Due to the ongoing evolution in transplant indications, HRSA anticipates incremental changes in information collected by the SCTOD to reflect current clinical care and facilitate statistical modeling; however, the agency does not anticipate these changes will significantly affect the reporting burden.

Proposed revisions fall into several categories and reflect the most up-to-date medical evidence. Revisions also include COVID-19 vaccine questions. Additional instructions are available in the Federal Register notice.